Missouri HB1717 modifies provisions for alternative therapies, including psilocybin, for therapeutic use.
Missouri HB1717 modifies provisions for alternative therapies, including psilocybin, for therapeutic use. The bill allows eligible patients to use psilocybin under specific conditions, such as having a terminal, life-threatening, or severely debilitating condition. It outlines requirements for facilitators, who must be licensed professionals, and mandates that the Department of Mental Health conduct a study on the efficacy of psilocybin for veterans with PTSD, major depressive disorder, or substance use disorders, or those requiring end-of-life care.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.